begelomab   

GtoPdb Ligand ID: 8691

Synonyms: Begendina&rg; (proprietary name) | BT 5/9 | SAND 26
Compound class: Antibody
Comment: Begelomab is an investigational murine monoclonal antibody targeting DPP4 (dipeptidyl-peptidase 4, a.k.a. CD26 T cell antigen).
Peptide sequence and structural information for begelomab is available from its IMGT/mAb-DB entry.
A search of patent literature reveals that the heavy chain variable region CDRs and light chain variable region CDRs of begelomab match sequences of anti-CD26 antibodies disclosed in FIG 2a of patent EP2767549 A1 [1].
Immunopharmacology Comments
Begelomab is a DPP4 (CD26)-targeting monoclonal antibody that was in Phase 3 clinical trial vs. conventional second-line treatment for steroid-resistant GvHD (see NCT02411084). The study appears to have been terminated on grounds of insufficient rate of participant recriutment. Mechanistically the antibody targets activated CD26+ T cells that appear to accumulate in the organs of patients with GvHD.
Immunopharmacology Disease
Disease X-Refs Comment References
Graft versus host disease Ex Phase 3 clinical candidate for steroid-resistant GvHD- see NCT02411084.